Sun Pharma introduces STARIZO to tackle drug-resistant skin infections in India
Sun Pharmaceutical Industries Limited has introduced STARIZO (Tedizolid Phosphate) to the Indian market, a novel antibacterial treatment targeting Acute Bacterial Skin and Skin Structure Infections ... Read More
Sun Pharmaceutical completes merger with Taro Pharmaceutical to enhance market position
Sun Pharmaceutical Industries Limited has announced the completion of its strategic merger with Taro Pharmaceutical Industries Ltd. (NYSE: TARO), marking a significant consolidation in the ... Read More
Sun Pharma gains Australian approval for Acne treatment Winlevi
Sun Pharmaceutical Industries Limited (Sun Pharma) has achieved a significant milestone in dermatology with the Australian Therapeutic Goods Administration (TGA)'s recent approval of Winlevi (clascoterone ... Read More
Sun Pharmaceutical proposes revised offer for Taro Pharmaceutical acquisition
In a notable development within the pharmaceutical industry, Sun Pharmaceutical Industries Limited has expressed a non-binding interest in acquiring shares of Taro Pharmaceutical Industries Ltd. ... Read More
Zydus Lifesciences, Sun Pharma to co-market Desidustat for CKD patients in India
Zydus Lifesciences Limited and Sun Pharmaceutical Industries Limited have announced a licensing agreement for the co-marketing of Desidustat, an innovative oral anemia treatment for Chronic ... Read More
Sun Pharma’s CEQUA shows sustained dry eye disease improvement in Phase 4 study
Sun Pharmaceutical Industries Limited has made a significant announcement regarding its groundbreaking product, CEQUA (cyclosporine ophthalmic solution) 0.09%. The company has unveiled Phase 4 data ... Read More
Sun Pharma’s NDA for Deuruxolitinib garners FDA nod: A potential leap for alopecia areata patients
Sun Pharmaceutical Industries Ltd announced that the U.S. Food and Drug Administration (FDA) has officially accepted the New Drug Application (NDA) for their investigational drug, ... Read More
Sun Pharma’s GL0034 yields promising results in two Phase 1 trials
Sun Pharmaceutical Industries has unveiled positive results from two Phase 1 studies assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of GL0034, a novel long-acting GLP-1 ... Read More
Sun Pharma gains Health Canada’s approval for WINLEVI for acne treatment
Sun Pharma Canada, a subsidiary of Sun Pharmaceutical Industries, has secured Health Canada's approval for their pioneering acne treatment, WINLEVI (clascoterone cream 1%). This marks ... Read More
MMP Industries bags packaging order from Sun Pharmaceutical
MMP Industries, a Nagpur-based manufacturer of aluminum powders, aluminum foils, and aluminum conductors, has bagged its first commercial order from Sun Pharmaceutical Industries for the ... Read More